Skip to main content
SpringerLink
Log in

Definition, Staging und Therapie

Das lokal fortgeschrittene Prostatakarzinom*

  • Zertifizierte Fortbildung
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

© Johannes Bründl

2

Literatur

  1. Robert Koch Institut - Zentrum für Krebsregisterdaten, Krebs in Deutschland - Prostata. https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2019/kid_2019_c61_prostata.pdf?__blob=publicationFile; abgerufen am 16. Mai 2021

  2. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Prostatakarzinom, Langversion 6.0, 2021, AWMF Registernummer: 043/022OL. http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom; abgerufen am 16. Mai 2021

  3. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer 2021. https://uroweb.org/guideline/prostatecancer; abgerufen am 16. Mai 2021

  4. Brierlley G et al (Hrsg). TNM classification of malignant tumours. Hoboken, New Jersey, USA: Wiley-Blackwell, 2017

  5. Solyanik O et al. Bildgebung des lokal fortgeschrittenen Prostatakarzinoms. Urologe A. 2017;56(11):1383-93

  6. Lee H et al. Accuracy of preoperative multiparametric magnetic resonance imaging for prediction of unfavorable pathology in patients with localized prostate cancer undergoing radical prostatectomy. World J Urol. 2017;35(6):929-34

  7. Pompe RS et al. Oncological and functional outcomes after radical prostatectomy for high or very high risk prostate cancer: European validation of the current NCCN® guideline. J Urol. 2017;198(2):354-61

  8. Deutsche Krebsgesellschaft - Jahresbericht der zertifizierten Prostatakrebszentren - Kennzahlenauswertung 2021. https://www.onkozert.de/wordpress/wp-content/uploads/2021/03/qualitaetsindikatoren_prostatakrebs_2021-A1_210317.pdf?v=96260693; abgerufen am 16. Mai 2021

  9. Akre O et al. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden. Eur Urol. 2011;60(3):554-63

  10. Boorjian SA et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011;117(13): 2883-91

  11. Sooriakumaran P et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ. 2014;348:g1502

  12. Hager B et al. Increasing use of radical prostatectomy for locally advanced prostate cancer in the USA and Germany: a comparative population-based study. Prostate Cancer Prostatic Dis. 2017;20(1):61-6

  13. Ward JF et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005;95(6):751-56

  14. Walz J et al. Pathological Results and Rates of Treatment Failure in High-Risk Prostate Cancer Patients After Radical Prostatectomy. BJU Int. 2011;107(5):765-70

  15. Amling C et al. Primary Surgical Therapy for Clinical Stage T3 Adenocarcinoma of the Prostate. Semin Urol Oncol. 1997;15(4):215-21

  16. Carver B. et al. Long-Term Outcome Following Radical Prostatectomy in Men with Clinical Stage T3 Prostate Cancer. J Urol. 2006;176(2):564-8

  17. Hsu C et al. Outcome of Surgery for Clinical Unilateral T3a Prostate Cancer: A Single-Institution Experience. Eur Urol. 2007; 51(1):121-8

  18. Sciarra A et al. Role of Radical Retropubic Prostatectomy in Patients with Locally Advanced Prostate Cancer: The Influence of Gleason Score 8-10. Urol Int. 2003;70(3):186-94

  19. Mazzone et al. Technical Refinements in Superextended Robot-assisted Radical Prostatectomy for Locally Advanced Prostate Cancer Patients at Multiparametric Resonance Imaging. Eur Urol. 2021;80(1):104-112

  20. Tewari A et al. Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy. Eur Urol. 2012;62(1):1-15

  21. Ham W et al. Robotic radical prostatectomy for patients with locally advanced prostate cancer is feasible: results of a singleinstitution study. J Laparoendosc Adv Surg Tech A. 2009;19(3):329-32

  22. Nyberg M et al. Functional and Oncologic Outcomes Between Open and Robotic Radical Prostatectomy at 24-month Follow-up in the Swedish LAPPRO Trial. Eur Urol Oncol. 2018;1(5):353-60

  23. Menon M et al. Biochemical Recurrence Following Robot-Assisted Radical Prostatectomy: Analysis of 1384 Patients with a Median 5-Year Follow-up. Eur Urol. 2010;58(6):838-46

  24. Mandel P et al. Incidence, Risk Factors, Management, and Complications of Rectal Injuries During Radical Prostatectomy. Eur Urol Focus. 2018;4(4):554-7

  25. Xia L et al. Associations between Hospital Volume and Outcomes of Robot-Assisted Radical Prostatectomy. J Urol. 2020;203(5):926-32

  26. Beyer B et al. A feasible and time-efficient adaption of NeuroSAFE for da Vinci robotassisted radical prostatectomy. Eur Urol. 2014;66(1):138-44

  27. Schlomm T et al. Neurovascular structureadjacent frozen-section examination (NeuroSAFE) increases nerve-sparing frequency and reduces positive surgical margins in open and robot-assisted laparoscopic radical prostatectomy: experience after 11,069 consecutive patients. Eur Urol. 2012;62(2):333-40

  28. Bader P et al. Disease Progression and Survival of Patients with Positive Lymph Nodes After Radical Prostatectomy. Is There a Chance of Cure? J Urol. 2003; 169(3):849-54

  29. Fossati N et al. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. Eur Urol. 2017;72(1):84-109

  30. Rexer H et al. Operative Studie zur Ausdehnung der Lymphadenektomie beim Intermediate- und High-risk-Prostatakarzinom. Forum. 2021;36(1)76-8

  31. Van der Poel H et al. Sequential treatment for recurrent localized prostate cancer. J Surg Oncol. 2008;97(5):377-82

  32. Widmark A et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomized phase III trial. Lancet. 2009;373(9660):301-8

  33. Akakura K et al. A Randomized Trial Comparing Radical Prostatectomy Plus Endocrine Therapy Versus External Beam Radiotherapy Plus Endocrine Therapy for Locally Advanced Prostate Cancer: Results at Median Follow-up of 102 Month. Jpn J Clin Oncol. 2006;36(12):789-93

  34. Saito T et al. Outcomes of Locally Advanced Prostate Cancer: A Single Institution Study of 209 Patients in Japan. Asian J Androl. 2006;8(5):555-61

  35. Edamura K et al. Long-Term Clinical Outcomes of 420 Consecutive Prostate Cancer Patients in a Single Institute. Acta Med Okayama. 2005;59(5):195-9

  36. Mandel P et al. Radikale Prostatektomie beim klinisch lokal fortgeschrittenen Prostatakarzinom. Urologe A. 2017;56(11):1394-401

  37. Berglund R et al. Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. Urology. 2012;79(3):633-7

  38. Eastham J et al. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. J Clin Oncol. 2020;38(26):3042-50

Download references

Danksagung

Die Autoren bedanken sich bei PD Dr. Christoph Nießen sowie Dr. Florian Weber für das radiologische sowie das histopathologische Bildmaterial.

Author information

Authors and Affiliations

  1. Klinik für Urologie der Universität Regensburg, Caritas-Krankenhaus St. Josef, Landshuter Str. 65, 93053, Regensburg, Deutschland

    Florian Girtner &  Johannes Bründl

  2. Klinik für Urologie Universität Regensburg, Caritas-Krankenhaus St. Josef, Landshuter Straße 65, 93053, Regensburg, Deutschland

    Maximilian Burger

Authors
  1. Florian Girtner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maximilian Burger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Johannes Bründl
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Girtner, F., Burger, M. & Bründl, J. Das lokal fortgeschrittene Prostatakarzinom*. InFo Hämatol Onkol 24, 42–50 (2021). https://doi.org/10.1007/s15004-021-8775-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-021-8775-7

Search

Navigation